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Abstract
Precision public health is a relatively new field that integrates components of precision medicine, such as human genomics
research, with public health concepts to help improve population health. Despite interest in advancing precision public
health initiatives using human genomics research, current and future opportunities in this emerging field remain largely
undescribed. To that end, we provide examples of promising opportunities and current applications of genomics research
within precision public health and outline future directions within five major domains of public health: biostatistics,
environmental health, epidemiology, health policy and health services, and social and behavioral science. To further extend
applications of genomics within precision public health research, three key cross-cutting challenges will need to be
addressed: developing policies that implement precision public health initiatives at multiple levels, improving data
integration and developing more rigorous methodologies, and incorporating initiatives that address health equity. Realizing
the potential to better integrate human genomics within precision public health will require transdisciplinary efforts that
leverage the strengths of both precision medicine and public health.
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Background
Precision medicine promises to revolutionize health by
incorporating individual-level characteristics (genetic,
lifestyle, environmental factors) into medical treatment
and prevention strategies to provide “the right care to
the right individual at the right time” [1]. This approach
allows for the application of individually tailored pre-
ventive or therapeutic medical interventions that may be
more effective than “one size fits all” approaches, thereby
improving quality of care and reducing unnecessary
diagnostic testing and therapies. It has been debated
whether precision-based approaches should be applied
not only to individual-level clinical care, but also to ef-
forts to improve health at a population level, i.e., preci-
sion public health [2–4]. While the relative merits of
targeted versus universal approaches to disease preven-
tion, treatment, and control at the population level re-
main the subject of debate, there is an increasing
recognition that more precise interventions can advance
health at a population level [5].
Precision public health is an approach that integrates
precision and population-based strategies to provide “the
right intervention to the right population at the right time”
[6]. This can include the scaling of precision medicine ini-
tiatives and the translation of basic-science discoveries to
the population level. A key aspect of precision public
health lies in its potential to develop more accurate
methods to identify multi-level risk factors and their im-
pact on population health and to use this information to
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develop targeted policies and programs to promote health
[7]. While other -omics approaches (e.g., transcriptomics,
proteomics, and metabolomics) are certainly relevant to
precision public health, incorporation of human genomics
into precision public health initiatives is particularly
promising given evidence of substantial heritability of
chronic diseases including obesity, cardiovascular disease,
and cancer, which are among the major public health
challenges of the twenty-first century [8, 9]. Thus, the use
of human genomics in precision public health can im-
prove measurement of individual-level factors that shape
health, serving as a conduit between precision medicine
and public health for improving health across individuals
and populations [7, 10].
To date, integrating human genomics research within
precision public health initiatives has supported more
precise disease prevention and control strategies, includ-
ing newborn screening and risk-stratified prevention
(e.g., enhanced cancer screening for individuals with
pathogenic BRCA1/2 variants) [11–13]. However, cur-
rently, application of human genomic research to the
translation of precision public health has been relatively
limited [14, 15]. Each of the major domains of public
health—biostatistics, environmental health, epidemi-
ology, health policy and services, and social and behav-
ioral health—offers complementary opportunities to
improve precision public health applications through hu-
man genomics [16]. Here, we describe examples of ini-
tiatives that integrate human genomics within precision
public health research, as well as opportunities to ad-
vance research in each of these public health domains.
Finally, we discuss challenges and opportunities to inte-
grating human genomics within the field of precision
public health that cut across the five major public health
domains.
Examples of integrating human genomics
research and public health
We describe ways by which the five domains of public
health endorsed by the Association of Schools and Pro-
grams of Public Health have integrated consideration of
human genomics within precision public health research.
The five domains include as follows: biostatistics, envir-
onmental health, epidemiology, health policy and health
services research, and social and behavioral health
(Table 1) [16].
Biostatistics involves the study of theories and tech-
niques for collecting, analyzing, and interpreting quanti-
tative data relevant to public health [16]. The immense
size and scale of the datasets used in precision public
health research necessitate advanced statistical methods
with enhanced approaches for reducing noise and en-
hancing signal detection. These datasets often include
multidimensional genetic biomarker data from large
numbers of subjects with serial measures repeated over
time [28]. Indeed, current genomic technologies allow
for the entire human genome to be sequenced through
whole genome sequencing. Results from the 1000 Ge-
nomes Project suggest that a typical human genome dif-
fers from the reference at 4.1 to 5 million sites [17]. In
addition to these genomic biomarkers, the ability to de-
tect other biomarkers including the transcriptome,
proteome, and metabolome is also increasing signifi-
cantly. Taken together, the scale of the individual bio-
marker data that is critical to advancing precision public
health, in addition to the complexity of modeling bio-
logic, behavioral, and environmental factors, is mathem-
atically challenging. Thus, the development of advanced
statistical methods that allow estimation of interactions
between individual-level (e.g., genetic, behavioral factors)
and macro-level factors (e.g., environmental exposures
and policies) and to identify latent relationships using
artificial intelligence (AI) will be necessary.
One example of existing precision public health initia-
tives within the biostatistics domain of public health is
the Genetic Analysis Workshop [18]. This is a collabor-
ation of genetic epidemiologists and statisticians who
evaluate and compare statistical genetic methods for
multi-omics data including evaluations of causal model-
ing for multi-omics data and of quality control of high-
throughput methylation data for epigenetics studies.
These efforts to improve data and modeling quality may
help to optimize algorithms for decision support in dis-
ease prevention and treatment contexts. Specific exam-
ples of this can already be seen for genomics with the
ASK2ME (All Syndromes Known to Man Evaluator),
which calculates risk of cancers associated with gene
variants using data from published studies [19]. Further
development of these types of methods and integration
with technology, such as the development of algorithms
for decision support tools and data resources using AI,
can improve risk-stratified cancer prevention and con-
trol efforts which are critical to advancing precision pub-
lic health.
Environmental health focuses on the interplay between
individuals and their environment to promote health.
The field of environmental health has long noted that
individual-level factors, such as genetics, interact with
macro-level environmental factors to impact population
health. The integration of human genomic research
within environmental health research may help to eluci-
date how individual-level factors (e.g., -omics data) and
macro-level factors interact to influence health, provid-
ing a better understanding of mechanisms underlying
complex gene-environment interactions. Understanding
how the “exposome” impacts disease development and
progression will allow precision public health researchers
to target and refine interventions for populations at high
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Table 1 Illustrative examples of study domains proposed for human genomics research in precision public health
Study domain and
definition
Promising opportunities Specific examples of
application in precision
public health
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resolution of statistical
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Lynch syndrome [23].
Evaluation of clinical utility,
cost-effectiveness, and
patient-reported outcomes
• Health Policy: ensuring
privacy of potentially highly
identifiable information.
Considerations of when






• Health Equity: integrate
consideration of the social
determinants of health
within health care (e.g.,
social prescribing).
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risk of poor health outcomes. For example, a gene-
environment interaction study using international cohort
data assessed whether the association between traffic-
related air pollution exposure and incident childhood
asthma was associated with genetic factors. Results iden-
tified an interaction with air pollution for three single-
nucleotide polymorphisms, suggesting that gene-
environment interactions may be associated with asthma
development [29]. Individuals with these known poly-
morphisms could be advised to limit time spent out-
doors on days where air pollution is particularly high, a
development that is already underway within smart city-
enabled built environment initiatives [30]. Other work
has identified potential gene-environment interactions
between workplace exposures to asbestos and family his-
tory of mesothelioma [31]; given increased risk of haz-
ardous workplace exposures among underserved
populations, this may have implications for our under-
standing of and interventions related to reducing socio-
economic disparities in health outcomes [32]. In another
example, investigators from the Parkinson’s Genes and
Environment Study collected mobile health technology
data, as well as environmental, genetic, and personal
health information longitudinally in order to better
understand the link between pesticide exposure, genet-
ics, and Parkinson’s disease [20, 21]. Future work to
understand mechanisms behind complex environmen-
tal exposures and their interactions with individual-
level factors may lead to environmental interventions
that target populations at high risk of adverse out-
comes [33, 34].
Epidemiology uses analytic methods to assess patterns
and causes of health states in populations, which encom-
pass individual-level characteristics (e.g., genetics) as well
as macro-level factors (e.g., neighborhood and commu-
nity characteristics). Precision public health draws on
epidemiological methods such as population-level
surveillance to improve knowledge of multi-level health
risk factors which can inform risk-stratified screening,
treatment, and prevention interventions. Given advances
in human genomic technologies, it is anticipated that
genomic information (along with other individual risk
factors) will be incorporated into precision public health
strategies [33, 35, 36]. These strategies, informed by gen-
etic epidemiological studies, will be critical to promoting
positive health-related practices [37, 38], risk-stratified
screening and treatment, reducing overdiagnosis, and
developing more personalized interventions [39–41]. To
this end, examples of human genomics research in epi-
demiology include investigating associations between
multiple common gene variants with disease risk [35, 42,
43], the relationship between genomic (polygenic) vari-
ants and monogenic variants [44], the contribution of
common variants to risk prediction models along with
other risk factors (potentially including other genetic risk
information, such as higher penetrance single genes) [45,
46], the role of genetics in identifying rare diseases in
newborn screening [4], the epigenome [47, 48], and the
interplay between biomarkers and drug response across
diverse communities [49–51]. For example, the
Northwest-Alaska Pharmacogenetics Research Network
is partnering with American Indian and Alaska Native
communities to identify known and novel genetic vari-
ants associated with drug response and health status in
their communities (vitamin D levels, vitamin K nutrition
sources, and metabolism related to blood clotting) [22].
Including racially/ethnically diverse populations in hu-
man genomic research, such as this one, will contribute
to a more generalizable evidence base to improve equity
of resulting precision public health interventions [22]. In
addition to understanding drug response, evidence from
another study that incorporated genetic information into
a risk prediction algorithm suggests that some women
may benefit from earlier than recommended breast
Table 1 Illustrative examples of study domains proposed for human genomics research in precision public health (Continued)
Study domain and
definition
Promising opportunities Specific examples of
application in precision
public health
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cancer screening, while other women may not be
harmed by delaying the start of routine screening [52].
Continued research examining genetic interactions with
contextual-level factors will inform more precise preven-
tion and screening which target those who stand to
benefit the most from these strategies [53].
Health policy and health services research examines
quality, cost, and access to health care among the popu-
lation. These data are essential to understand the eco-
nomic and health impact of precision public health
initiatives, including whether they support health equity.
With the evolution of genomic testing in both treatment
and prevention settings, health services research will be
key in the evaluation of clinical utility, cost-effectiveness,
and patient-reported outcomes. These data will be es-
sential in building the evidence base needed for policy-
makers and practitioners alike to translate human
genomic research in precision public health to benefit
populations. In particular, the field of implementation
science has the potential to play a pivotal role in lever-
aging precision medicine to benefit population health
and to promote health equity (i.e., enabling precision
public health) [54–56]. Implementation science is the
study of strategies to adopt and integrate evidence-based
health interventions such as those generated within the
field of genomic medicine into clinical and community
settings to improve individual outcomes and benefit
population health [57]. Currently, the Implementing
Genomic in Practice Consortium [23], funded by the
National Human Genome Research Institute, is seeking
to enhance the use of genomic medicine in part by inte-
grating implementation science frameworks into delivery
of precision medicine. These efforts have resulted in the
development of implementation guides for health care
systems, clinics, and provider champions who are inter-
ested in implementing pharmacogenomics testing [58,
59]. More specifically, the Consortium has developed
guidance for implementing and maintaining CYP2D6
testing to guide opioid prescribing as well as CYP2C19
testing for clopidogrel prescription [58]. Across the
world, implementation science is at the forefront of hu-
man genomics programs and precision public health ini-
tiatives, a further example being the Australian
Genomics Health Alliance. This national partnership
aims to assess the integration of human genomics into
the public healthcare system, using implementation sci-
ence to guide and evaluate the various efforts across
more than 80 organizations [60]. Research by this Alli-
ance studying the implementation of ultra-rapid exome
sequencing in the neonatal or pediatric intensive care
setting has highlighted the complexity of healthcare sys-
tems and the necessity of adapting to local context, fos-
tering participatory culture, collective learning, and
distributed leadership [61].
Social and behavioral research studies ways that be-
haviors and the conditions of daily life (i.e., the social de-
terminants of health) shape health across the life course
[62]. Historically, social and behavioral research related
to precision public health has focused on ethical, legal,
and social implications (ELSI) of human genomics re-
search [24]. Given the more traditional understanding of
genetics as being familial, social and behavioral research
has contributed to understanding the ELSI of sharing
genetic information with family members by exploring
concepts such as autonomy and beneficence. Numerous
calls have also been made for social and behavioral re-
searchers to go beyond impacting human genomics re-
search by integrating human genomics considerations
within precision public health initiatives [63, 64]. Exam-
ples of current and future precision public health re-
search opportunities in the social and behavioral
sciences include: improving public understanding of
genomics and data sharing, genetic and genomic risk
communication, expanding the reach of precision public
health interventions, developing and testing precision
public health interventions to promote behavior change,
and identifying new and/or more precise behavioral tar-
gets that may be informed by precision public health ap-
proaches [65]. Research in this area promises to improve
public trust and willingness to participate in interven-
tions that address their genetic risks.
To date, social and behavioral scientists have made
progress in translating genomic applications for the
benefit of population health by using community-based
genomic research that includes communities as partners
in human genomic research [53, 66]. For example, the
North Carolina Clinical Genomic Evaluation by Next-
generation Exome Sequencing 2 (NCGENES2), a diag-
nostic genomic sequencing study for children with un-
diagnosed conditions, explored the impact of a
Community Consult Team consisting of clinicians and
caregivers in order to maximize the utility and equity of
genomic sequencing [25]. Engaging this team resulted in
adaptations to the study protocol and materials, demon-
strating the valuable contribution of community engage-
ment to inform the implementation of translational
human genomics research [67]. Another example, the
Quebec CARTaGENE project, a large-scale genetic data-
base that serves as a public research platform, engaged
the public about their willingness to participate in such
a project. The first public engagement highlighted the
importance of transparency, maintaining confidentiality,
and ensuring the ability for donors to provide feedback
and guidance. Further, the team found a need to tailor
and target communication about the project across pa-
tient populations [26, 27]. Other related research has in-
corporated the patient voice by assessing patient and
family preferences for learning genomics information in
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order to inform family-based interventions that aim to
disseminate genetic information to families at high risk
of disease [68–72].
Cross-cutting challenges and opportunities for
integrating human genomics research within
precision public health
As demonstrated by examples from the field, principles
of precision public health are being applied by re-
searchers working at the intersections of precision medi-
cine, genomics, and public health. In addition to
domain-specific advances, innovations cutting across all
domains are needed to advance precision public health
initiatives, including (1) revised health policies, (2) im-
proved data integration and development of more rigor-
ous methodologies, and (3) an emphasis on health
equity (Table 1) [73–75].
Health policies at all levels including clinic, industry,
health system, state, and federal will need to adapt to
rapidly growing precision-based approaches in order to
support the goals of precision public health.
The development of new policies focused on ensuring
the privacy, confidentiality, and regulation of genetic re-
sults delivered to individuals will be important as preci-
sion public health becomes more established due to the
potential for precision health data to be highly identifi-
able. Further, as our ability to predict public health out-
comes improves, we must consider when and how to
intervene and the ethical and legal ramifications of ac-
tion or inaction. For example, researchers have identified
a link between child abuse and antisocial behavior with a
common monoamine oxidase (MAOA) gene variant
[76]. A meta-analysis of 27 studies identified a robust as-
sociation between increased likelihood of antisocial out-
comes after childhood adversity among carriers of the
low-activity MAOA genotype. Definitions of childhood
adversity and antisocial behavior varied, with the stron-
gest association with childhood maltreatment. However,
an intervention based on these data, presumably to re-
duce child abuse, should be a universal goal and not tar-
geted towards a specific subpopulation with low-activity
MAOA genotype. With each new epidemiological asso-
ciation, policymakers must decide whether and how the
results should be used to advance precision public
health. Policies that are proactive in addressing the
changing landscape will be essential, as rapid advances
in precision public health become available. Experience
with ELSI could help inform decision making about
these new discoveries and how they can be ethically im-
plemented and translated into new policies. Specifically,
there are a number of Centers of Excellence in ELSI Re-
search (CEER) funded by the National Human Genome
Research Institute. These projects use interdisciplinary
approaches to address complex and rapidly emerging
ethical, legal, and societal issues that occur as research
advances in genomics [77].
In addition, certain limitations in current policies must
be addressed. For example, in the USA, the Genetic In-
formation Non-Discrimination Act fails to protect the
public from life insurance discrimination based on pre-
existing genetic conditions, most greatly impacting so-
cioeconomically vulnerable citizens who may not be able
to afford life insurance rates that are raised due to their
genetic risks [78]. Conversely, US state-level genetic
privacy laws may inhibit the sharing of important genetic
information with relatives, and while this may be im-
portant in protecting genetic privacy, it may also compli-
cate precision public health efforts to implement cascade
screening (or family genetic testing) to identify and man-
age disease risk among individuals with highly penetrant
genetic conditions [79]. Future research studying the im-
pact of current policies, as well as barriers and facilita-
tors to enacting these policies, will be essential for
building a policy landscape that facilitates precision pub-
lic health.
Improved data integration and methods will be neces-
sary to leverage the complexity of human genomics data
for addressing precision public health problems. Incorpor-
ating these data with other individual-, interpersonal-,
community-, and environmental-level data in a meaning-
ful and rigorous way will require novel methods for data
measurement, collection, management, and integration
[73]. In particular, advanced informatics is needed to fulfill
the opportunities and meet the challenges of integrating
human genomic research within precision public health
through information technology infrastructure develop-
ment [74]. As the underpinnings of multi-level mecha-
nisms take shape, multi-level systems-based interventions
will be necessary. These include study designs and data
storage infrastructure that allow researchers to understand
both the synergistic and independent effects of these com-
plex problems and multi-level solutions across diverse
populations. Future opportunities in this area include im-
proving complex study designs and big data management
and storage. In addition, researchers will need secure data
systems that allow data to be shared efficiently and ethic-
ally between researchers and public health agencies and
practitioners. Further, data integration of genomic and
other precision public health data into the electronic
health record with appropriate decision support will be
important in integrating these data into the clinical setting
to improve health [75, 80, 81].
One application of improved data integration and re-
lated methods to help address precision public health
problems is through the use of conditional random for-
ests (a machine learning approach). Nau et al. used this
approach to identify features of social, food, and physical
activity environments that jointly predicted whether a
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community’s environment could be considered as pri-
marily obesogenic or obesoprotective [82]. The authors
used a dichotomous indicator of average BMI z-score
among children living in each community as a proxy for
each of these outcomes. Of the 44 community character-
istics examined, a combination of 13 features of the so-
cial, food, and physical activity environment correctly
classified two-thirds of communities as obesogenic or
obesoprotective, with social features being the most in-
formative in this respect. This study offers a way forward
in use of large datasets to help define more precise tar-
gets for public health intervention, which are critical to
precision public health initiatives.
Health equity, or fair access to resources that allow for
an individual to reach their full health potential, is inte-
gral to the future of precision public health. Broadly, en-
suring health equity requires that individuals have access
to appropriate resources regardless of their social pos-
ition or circumstances. As it relates to precision public
health, Olstad and McIntyre specifically define “precision
public health” as “the study of how multiple dimensions
of social position interact to confer health risk differently
for precisely defined population subgroups according to
the social contexts in which they are embedded, while
considering relevant biological and behavioral factors”
[7]. Enhancing attention to health equity is perhaps the
most important opportunity for the intersection of preci-
sion- and population-based approaches if we are to en-
sure that precision public health retains its focus on
improving health for all members of society, and the
health of marginalized groups in particular [53, 83].
Unfortunately, racial, ethnic, and socioeconomic dis-
parities in access to precision approaches, including gen-
etic testing, have already emerged [84, 85]. For example ,
underrepresentation of racial and ethnic minority popu-
lations in genomic databases limits the benefit of newly
developed tools for assessing risk, prognosis, and thera-
peutic response for patients who already experience lim-
ited access to and poorer quality of healthcare due to
factors such as poverty and systemic racism [86]. Spe-
cific efforts have been taken to implement genomic
screening for hereditary breast and ovarian cancer syn-
drome (HBOC), Lynch syndrome (LS), and familial
hypercholesterolemia (FH) among diverse populations
(i.e., non-European ancestry populations) that are com-
monly excluded in genomic medicine research [87].
Most participants in this diverse sample opted for the
return of results, with younger participants, female par-
ticipants, and Hispanic/Latinx participants being most
likely to opt to receive their results [88].
Community engagement, a cornerstone of public
health research, may facilitate the implementation of
precision public health initiatives seeking to promote
health equity [10]. Indeed, initiatives such as the All of
Us Research Program have recognized a need to restore
trust among underserved and historically marginalized
groups, such as Black, LatinX, and Indigenous American
groups, to participate in health research through com-
munity engagement principles [89, 90]. Thus, it is crit-
ical to ensure that equity remains a core concern within
precision public health initiatives [91]. With its emphasis
on health equity and incorporating multiple levels of in-
fluence on population health, human genomic research
can play a major role in precision public health research
that impacts population health [92]. This can be
achieved through increasing inclusion of underrepre-
sented populations in genomics research to ensure that
all of society shares in the economic and health benefits
of precision public health investments [93].
Conclusions
While challenges lie ahead, the increased integration of
human genomics research in precision public health is
expected to provide opportunities for improving popula-
tion health. To this end, there is a need to consider the
most acceptable and effective way to scale advances in
human genomic research to benefit populations by bet-
ter targeting disease prevention, treatment, and control
efforts. Transdisciplinary research that draws from preci-
sion medicine, genomics, and public health can continue
to serve as a needed conduit towards the realization of
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